US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

10.91

-0.2500-2.24%

Post-market: 10.85-0.0600-0.55%17:23 EDT

Volume:223.69K

Turnover:2.50M

Market Cap:588.97M

PE:-1.74

High:11.50

Open:11.08

Low:10.82

Close:11.16

52wk High:17.40

52wk Low:7.90

Shares:53.98M

Float Shares:17.65M

Volume Ratio:0.55

T/O Rate:1.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.2610

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:1.07

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026

Eikon to present six abstracts at ASCO annual meeting

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics price target lowered to $5 from $7 at Wedbush

Eikon Therapeutics Is Maintained at Underperform by Wedbush

Analyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline

Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating

MT Newswires Live

Eikon Therapeutics Highlights Q1 2026 Results and Pipeline

Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate

Eikon Therapeutics Q1 net loss widens to $83 million

Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics Price Target Maintained With a $7.00/Share by Wedbush

J.P. Morgan Sticks to Their Buy Rating for Eikon Therapeutics, Inc. (EIKN)

Eikon FY25 net loss widens 37% to $333.6 million

Press Release: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

BUZZ-Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends

BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target

MT Newswires Live

Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald

Eikon Therapeutics Initiated at Buy by B of A Securities

Eikon Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating and Price Objective $34

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EIKN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":10.91,"timestamp":1779480000000,"preClose":11.16,"halted":0,"volume":223685,"hourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.91,"latestTime":"17:23 EDT","volume":20859,"amount":235365.89,"timestamp":1779485023477,"change":-0.06,"changeRate":-0.0055,"amplitude":0.082493},"delay":0,"changeRate":-0.022401433691756272,"floatShares":17648000,"shares":53984300,"eps":-6.261028,"marketStatus":"Closed Memorial Day","change":-0.25,"latestTime":"05-22 16:00:00 EDT","open":11.08,"high":11.5,"low":10.8248,"amount":2497767,"amplitude":0.060502,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.261028,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":11.16,"preHourTrading":{"tag":"盘前","latestPrice":10.82,"preClose":11.16,"latestTime":"04:01 EDT","volume":1,"amount":10.82,"timestamp":1779436861734,"change":-0.34,"changeRate":-0.030466,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.85,"preClose":10.91,"latestTime":"17:23 EDT","volume":20859,"amount":235365.89,"timestamp":1779485023477,"change":-0.06,"changeRate":-0.0055,"amplitude":0.082493},"volumeRatio":0.5483502795797158},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.5483502795797158,"shares":53984300,"dividePrice":0,"high":11.5,"amplitude":0.060502,"preClose":11.16,"low":10.8248,"week52Low":7.9,"pbRate":"1.07","week52High":17.4,"institutionHeld":0,"latestPrice":10.91,"eps":-6.261028,"divideRate":0,"volume":223685,"delay":0,"ttmEps":-6.261028,"open":11.08,"prevYearClose":18,"prevWeekClose":10.91,"prevMonthClose":9.615,"prevQuarterClose":10.58,"fiveDayClose":13.25,"twentyDayClose":9.655,"sixtyDayClose":13.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-05-22","current":-1.742525,"percent":0.648649,"low":-3.139466,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"high":-1.429233,"avg":-2.047009,"sd":0.418194,"marketCap":604186273},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273}],"updateTime":1779701968558},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637368971","title":"Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368971?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:19","pubTimestamp":1779405560,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics on May 21, 2026 flagged six oncology abstracts that will be presented at the 2026 ASCO annual meeting starting May 29, 2026.Planned presentations highlight ongoing mid- to late-stage studies of EIK1001 in first-line stage 4 non-small cell lung cancer, including combinations with standard regimens, with an update focused on efficacy, safety, and immune-response profiling.Additional abstracts will outline early clinical progress for EIK1003 in advanced solid tumors, including combination use with paclitaxel, alongside updated monotherapy findings.EIK1005 updates will cover first-in-human safety and pharmacokinetics in healthy participants, with a separate trial design for use alone or with pembrolizumab in advanced solid tumors such as MSI-H or dMMR cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL2RsHWf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357662","title":"Eikon to present six abstracts at ASCO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357662?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:12","pubTimestamp":1779397923,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics will present six oncology abstracts at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago starting May 29, 2026.Data presentations will cover EIK1001 in first-line stage 4 non-small cell lung cancer, including combination regimens with pembrolizumab.Additional updates will include EIK1003 results in advanced solid tumors, including combination work with paclitaxel, alongside early clinical progress for WRN inhibitor candidate EIK1005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1lZ1YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357327","title":"Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357327","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357327?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:05","pubTimestamp":1779397500,"startTime":"0","endTime":"0","summary":"Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299796/0/en/Eikon-Therapeutics-Announces-Availability-of-Six-Abstracts-for-Presentation-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","AFG","BK4117","BK4139","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246421","title":"Eikon Therapeutics price target lowered to $5 from $7 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246421","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246421?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:33","pubTimestamp":1778603632,"startTime":"0","endTime":"0","summary":"Wedbush lowered the firm’s price target on Eikon Therapeutics (EIKN) to $5 from $7 and keeps an Underperform rating on the shares after the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-5-from-7-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634117362","title":"Eikon Therapeutics Is Maintained at Underperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2634117362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634117362?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:48","pubTimestamp":1778590080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 08:48 ET (12:48 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634221925","title":"Analyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2634221925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634221925?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:15","pubTimestamp":1778588148,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Eikon Therapeutics, Inc., with a price target of $29.00. Br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eikon-therapeutics-maintaining-29-december-2026-price-target-on-emerging-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eikon-therapeutics-maintaining-29-december-2026-price-target-on-emerging-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634660219","title":"Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2634660219","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634660219?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:11","pubTimestamp":1778587905,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) has an average rating of overweight and mean price target of $25.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253519","title":"Eikon Therapeutics Highlights Q1 2026 Results and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253519","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253519?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:06","pubTimestamp":1778533583,"startTime":"0","endTime":"0","summary":"An announcement from Eikon Therapeutics, Inc. ( ($EIKN) ) is now available. Eikon Therapeutics reported its first quarter 2026 results on May 11, 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q1-2026-results-and-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-highlights-q1-2026-results-and-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237439","title":"Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237439","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237439?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:19","pubTimestamp":1778530780,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(4.07) by 39.56 percent. This is a 90.86 percent increase over losses of $(26.91) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52469251/eikon-therapeutics-q1-eps-2-46-beats-4-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634023717","title":"Eikon Therapeutics Q1 net loss widens to $83 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634023717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634023717?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:17","pubTimestamp":1778530671,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics reported a net loss attributable to common stockholders that widened to USD 83 million, while R&D expense climbed 24% to USD 70 million.G&A expense rose 17% to USD 17.3 million; cash, cash equivalents, and marketable securities totaled USD 596 million as of March 31, 2026.R&D increase reflected accelerating clinical trial activity and a USD 5 million milestone payment to Impact Therapeutics tied to advancing EIK1003 into Phase 2 development.Eikon forecast current cash resources to fund operations into the second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLhWGMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232507","title":"Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232507","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232507?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:02","pubTimestamp":1778529720,"startTime":"0","endTime":"0","summary":"-- Maintained strong financial position with $596 million in cash, cash. equivalents and marketable securities as of March 31, 2026. -- Continued execution across the oncology pipeline, with a strategic focus. on three priority programs: EIK1001, a Toll-like receptor 7/8 . agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor,-- Six abstracts accepted for the American Society of Clinical Oncology.  annual meeting highlighting new data from the company's lead. programs including new safety, tolerability, and efficacy data. discovery programs in the absence of robust biochemical assays. \"We made meaningful progress in the first quarter advancing our oncology programs and expanding the clinical evidence supporting their potential, \" said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics. \"We are particularly encouraged by the breadth of data emerging across our pipeline, which will be featured at the ASCO annual meeting, and we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4588","BK4585","LU2487616109.SGD","BK4139","L","LU0053666078.USD","BK4107","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580208","title":"Eikon Therapeutics Price Target Maintained With a $7.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623580208?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:27","pubTimestamp":1774967220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:27 ET (14:27 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623158770","title":"J.P. Morgan Sticks to Their Buy Rating for Eikon Therapeutics, Inc. (EIKN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623158770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623158770?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:56","pubTimestamp":1774965401,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Cheng from J.P. Morgan reiterated a Buy rating on Eikon Therapeutics, Inc., with a price target of $29.00. Ch...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-eikon-therapeutics-inc-eikn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-eikon-therapeutics-inc-eikn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623138312","title":"Eikon FY25 net loss widens 37% to $333.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623138312","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623138312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:55","pubTimestamp":1774871710,"startTime":"0","endTime":"0","summary":"Eikon posted a full-year net loss attributable to common stockholders of $334 million, widening from $244 million.Operating loss expanded to $339 million as research and development expense climbed 22% to $250 million.General and administrative costs jumped 59% to $89 million, driven mainly by a $21 million impairment tied to vacated properties.Cash, cash equivalents, and marketable securities totaled $336 million at year-end; an upsized IPO in February raised $381 million in gross proceeds.Completed enrollment in TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 non-small cell lung cancer, with a comprehensive data set expected in 2H 2026; cash runway forecast into 2H 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eiko","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL95SGYj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312506","title":"Press Release: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312506","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312506?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:48","pubTimestamp":1774871280,"startTime":"0","endTime":"0","summary":"-- Closed upsized initial public offering in February 2026, raising $381. -- Completed enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in. first-line treatment of stage 4 non-small cell lung cancer. MILLBRAE, Calif., March 30, 2026  -- Eikon Therapeutics, Inc.  , a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates.\"2025 was an important year of progress for Eikon's business and clinical programs,\" said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. \"With our initial public offering, and the consequent strengthening of our balance sheet, we believe we are well-positioned to advance multiple registration-enabling programs, bringing us closer to our mission of delivering breakthrough therapeutics to patients with serious illnesses.\". EIK1001 is a systemically administ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2487616109.SGD","BK4585","EIKN","BK4107","LU0210528500.USD","L","BK4139","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616505083","title":"BUZZ-Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends","url":"https://stock-news.laohu8.com/highlight/detail?id=2616505083","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616505083?lang=en_us&edition=fundamental","pubTime":"2026-03-03 02:09","pubTimestamp":1772474994,"startTime":"0","endTime":"0","summary":"BUZZ-Perlmutter-backed Eikon Therapeutics rises as IPO research quiet period ends** Shares of drug developer Eikon Therapeutics EIKN.O, headed by Merck veteran Roger Perlmutter, rise 3.9% to $14.31** At least three Wall Street brokerages initiate coverage with bullish ratings as IPO research quiet period ends** \"EIKN’s portfolio, led by Keytruda ex-developers, is strategically positioned with two advanced assets through in-licenses and a homegrown pipeline built from its super resolution microscopy discovery engine,\" J.P. Morgan says** Co's most advanced candidate, EIK1001, in combination with Keytruda, is in a mid- to late-stage study to treat a type of skin cancer** EIKN went public in New York last month after selling 21.2 million shares in an IPO priced at $18 apiece** J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho were underwriters for EIKN's offering** As of last close, EIKN stock down 23% since February debut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4N3ZQ1F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051225.USD","SG9999001440.SGD","LU0965509101.SGD","LU2129689431.USD","LU0058720904.USD","SG9999014559.SGD","SG9999015358.SGD","SG9999015341.SGD","IE00BFXG1179.USD","LU1934455277.USD","BK4534","LU2361044949.HKD","SG9999014542.SGD","IE00B4R5TH58.HKD","LU0314106906.USD","LU0985320562.USD","SG9999014567.USD","BK4516","LU1201861165.SGD","LU0320765489.SGD","LU2129689514.USD","LU0306807586.USD","BK4533","IE00B7SZLL34.SGD","LU0208291251.USD","LU2106854487.HKD","LU0868494617.USD","LU0965509010.AUD","BK4559","LU1037948897.HKD","LU1804176565.USD","SG9999001176.SGD","LU1880398471.USD","LU0053666078.USD","LU2023250504.SGD","LU1880398554.USD","LU0256863811.USD","LU1585245621.USD","LU1069347547.HKD","LU1291159041.SGD","LU0203345920.USD","LU0130103400.USD","LU1267930227.SGD","IE0002141913.USD","SG9999013999.USD","LU2324357040.USD","LU1934455194.USD","BK4504","LU0149725797.USD","LU0640476718.USD","LU0234570918.USD","SGXZ57979304.SGD","LU1116320901.HKD","LU0306806265.USD","LU1989772923.USD","LU1571399168.USD","BK4550","LU1791807156.HKD","LU0211331839.USD","LU1718418525.SGD","LU0106261372.USD","LU1066051498.USD","IE00B19Z3B42.SGD","EIKN","LU0861579265.USD","LU0971096721.USD","LU1894683348.USD","LU1941712348.USD","BK4553","SG9999001176.USD","LU1668664300.SGD","LU0256863902.USD","LU0648000940.SGD","LU0432979614.USD","LU1496350171.SGD","LU1941712264.USD","IE00BLSP4452.SGD","IE0009355771.USD","IE00BN8TJ469.HKD","LU0683600562.USD","LU1201861249.SGD","LU1974910355.USD","LU2361044865.SGD","IE0001KFT4U8.USD","LU1162221912.USD","BK4207","LU1093756168.USD","LU1280957306.USD","IE00B2B36J28.USD","LU2133065610.SGD","SG9999014575.USD","LU0106831901.USD","LU1894683264.USD","LU0006306889.USD","BK4139","LU0203347892.USD","LU1989771016.USD","LU1035773651.USD","LU1934455863.HKD","LU2023250843.SGD","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2129689605.HKD","LU0787776722.HKD","LU0289739699.SGD","LU1883839398.USD","IE0034235188.USD","LU1917777945.USD","LU1037948541.HKD","LU1699723380.USD","SG9999002232.USD","BK4585","LU1363072403.SGD","LU0170899867.USD","IE00BJJMRZ35.SGD","LU0477156953.USD","LU0265550359.USD","IE00B19Z3581.USD","LU0417517546.SGD","BK4581","IE00BKVL7J92.USD","LU0320765646.SGD","LU1066053197.SGD","LU1506573853.SGD","LU0965509283.SGD","LU0128525689.USD","LU1366192091.USD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0648001328.SGD","LU1496350502.SGD","LU1057294990.SGD","IE00BLSP4239.USD","BK4588","IE000M9KFDE8.USD","LU1061106388.HKD","LU2461242641.AUD","LU1929549753.HKD","LU1066051811.HKD","LU0965508806.USD","LU2125154935.USD","LU1983299246.USD","LU0310800965.SGD","LU1989772840.SGD","LU0052756011.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU0098860793.USD","LU0321505439.SGD","LU0321505868.SGD","LU0130518102.USD","LU1093756325.SGD","LU2125154778.USD","LU1430594728.SGD","LU2265009873.SGD","IE00BZ1G4Q59.USD","SG9999002224.SGD","IE00BJT1NW94.SGD","LU0130102774.USD","LU2089984988.USD","LU0980610538.SGD","LU1023059063.AUD","LU0070302665.USD","LU0122379950.USD","LU0265550946.USD","BK4007","LU2361045086.USD","IE0002270589.USD","LU0266013472.USD","LU0477156797.USD","LU1116320737.USD","LU2112291526.USD","LU2468319806.SGD","LU0130517989.USD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616711359","title":"BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616711359","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616711359?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:39","pubTimestamp":1772462372,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) has an average rating of overweight and mean price target of $25.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616588473","title":"Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2616588473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616588473?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:58","pubTimestamp":1772459881,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Eikon Therapeutics (EIKN) with an Overweight rating. Eikon is a development-stage oncology company built ar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616333990","title":"Eikon Therapeutics Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616333990?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:56","pubTimestamp":1772452560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EIKN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 06:56 ET (11:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616133602","title":"Eikon Therapeutics Inc : Bofa Global Research Initiates Coverage With  Buy Rating and Price Objective $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2616133602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616133602?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:42","pubTimestamp":1772451735,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0O9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}